Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29425228 | 1.00 | PAX8 (0.32) | PAX8ALDH1A1 | |
| SCHEMBL10511364 | 1.00 | PAX8 (0.32) | PAX8ALDH1A1 | |
| SCHEMBL30655986 | 1.00 | PAX8 (0.32) | PAX8ALDH1A1 | |
| SCHEMBL29009630 | 1.00 | PAX8 (0.32) | PAX8ALDH1A1 | |
| SCHEMBL524648 | 1.00 | PAX8 (0.32) | PAX8ALDH1A1 | |
| SCHEMBL31006936 | 1.00 | PAX8 (0.32) | PAX8ALDH1A1 | |
| SCHEMBL2510639 | 1.00 | PAX8 (0.32) | PAX8ALDH1A1 | |
| SCHEMBL6384699 | 1.00 | PAX8 (0.32) | PAX8ALDH1A1 | |
| SCHEMBL1673169 | 1.00 | PAX8 (0.32) | PAX8ALDH1A1 | |
| SCHEMBL702670 | 1.00 | PAX8 (0.32) | PAX8ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 161 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617873-B2 | Method of purifying polysaccharides | LONZA LTD (CH) | 2026-05-05 | — | — | US | claimed |
| US-20250295790-A1 | LECTIN-TARGETING CONJUGATES | HELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH (DE) | 2025-09-25 | — | — | US | claimed |
| EP-4608849-A1 | SACCHARIDE IMPORTERS FOR LACTO-N-TRIOSE | Inbiose N.V. (BE) | 2025-09-03 | — | — | EP | claimed |
| EP-4444355-A2 | LECTIN-TARGETING CONJUGATES | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2024-10-16 | — | — | EP | claimed |
| CN-118525086-A | Production of alpha-1, 3-fucosylated compounds | 因比奥斯公司 | 2024-08-20 | — | — | CN | claimed |
| CN-118414434-A | Production of alpha-1, 4-fucosylated compounds | 因比奥斯公司 | 2024-07-30 | — | — | CN | claimed |
| WO-2024089131-A1 | SACCHARIDE IMPORTERS FOR LACTO-N-TRIOSE | INBIOSE N.V. (BE) | 2024-05-02 | — | — | WO | claimed |
| EP-4323512-A1 | CELLULAR PRODUCTION OF BIOPRODUCTS | Inbiose N.V. (BE) | 2024-02-21 | — | — | EP | claimed |
| EP-4323510-A1 | CELLULAR PRODUCTION OF SIALYLATED DI- AND/OR OLIGOSACCHARIDES | Inbiose N.V. (BE) | 2024-02-21 | — | — | EP | claimed |
| EP-4323507-A2 | FERMENTATIVE PRODUCTION | Inbiose N.V. (BE) | 2024-02-21 | — | — | EP | claimed |
| WO-2022219188-A1 | CELLULAR PRODUCTION OF SIALYLATED DI- AND/OR OLIGOSACCHARIDES | INBIOSE N.V. (BE) | 2022-10-20 | — | — | WO | claimed |
| WO-2022219186-A2 | FERMENTATIVE PRODUCTION | INBIOSE N.V. (BE) | 2022-10-20 | — | — | WO | claimed |
| EP-4065162-A1 | METHOD OF PURIFYING POLYSACCHARIDES | Lonza Ltd (CH) | 2022-10-05 | — | — | EP | claimed |
| WO-2022157213-A1 | PRODUCTION OF OLIGOSACCHARIDES COMPRISING LN3 AS CORE STRUCTURE IN HOST CELLS | INBIOSE N.V. (BE) | 2022-07-28 | — | — | WO | claimed |
| WO-2022152914-A1 | CELLULAR PRODUCTION OF GLYCOSYLATED PRODUCTS | INBIOSE N.V. (BE) | 2022-07-21 | — | — | WO | claimed |
| CN-114667157-A | Method for purifying polysaccharides | 龙沙有限公司 | 2022-06-24 | — | — | CN | claimed |
| WO-2022129470-A1 | VARIANT SUCROSE PERMEASE POLYPEPTIDES | INBIOSE N.V. (BE) | 2022-06-23 | — | — | WO | claimed |
| WO-2022034076-A2 | PRODUCTION OF GALACTOSYLATED DI- AND OLIGOSACCHARIDES | INBIOSE N.V. (BE) | 2022-02-17 | — | — | WO | claimed |
| WO-2022034069-A1 | PRODUCTION OF A MIXTURE OF NEUTRAL FUCOSYLATED OLIGOSACCHARIDES BY A CELL | INBIOSE N.V. (BE) | 2022-02-17 | — | — | WO | claimed |
| WO-2021108792-A1 | METHOD OF PURIFYING POLYSACCHARIDES | LONZA LTD (CH) | 2021-06-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250295790-A1 | LECTIN-TARGETING CONJUGATES | MASP2, LGALS3BP, LGALS1 | PAX8 3905/4885ALDH1A1 3861/4885 |
| US-12617873-B2 | Method of purifying polysaccharides | CD47, CD69, CFB | PAX8 4585/4885ALDH1A1 4879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.